National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ocrelizumab (Ocrevus®) is indicated for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.

NCPE Assessment Process Ongoing
Rapid review received 29/11/2017
Rapid review completed 14/12/2017
Rapid Review outcome Full Pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 17/01/2018
Pre-submission consultation with Applicant 20/02/2018
Submission received from Applicant 27/03/2018
Preliminary review sent to Applicant 08/06/2018
NCPE assessment re-commenced 06/07/2018
Factual accuracy sent to Applicant 30/08/2018
NCPE assessment re-commenced 07/09/2018
NCPE assessment completed 04/10/2018
NCPE assessment outcome The NCPE recommends that ocrelizumab (Ocrevus®) not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Summary